NEW DELHI :
Mumbai-based Pharmaceutical company Cipla Ltd acquired a novel and patented anti-infective product, Elores, from Venus Remedies Ltd, the company said in an exchange filing.
Cipla did not give financial details of the acquisition.
"Elores underscores our commitment to anti-microbial stewardship and is a significant addition to our branded portfolio of anti-infectives in India. We recently acquired Zemdri, and with the acquisition of Elores, we have added to our offering of new generation antibiotics," Cipla Managing Director and Chief Executive Officer Umang Vohra said as per the statement.
The drug was launched in India in 2013 after approval from the Drug Controller General of India.
Elores is indicated for treatment of life threatening infections caused by gram-negative bacteria, and the company said that the medicine is part of its strategy to fight anti-microbial resistance.
The novel medicine is a combination of ceftriaxone, sulbactam and Disodium ethylenediaminetetraacetic acid (EDTA).
Elores preserves the efficacy of the antibiotic using disodium EDTA, which is an antibiotic resistance breakers (ARB), Cipla said. An ARB is not an antibiotic itself but overcomes resistance barriers of the bacteria and in the process facilitates anti-microbial activity of the drug.
In the recently concluded Phase-3 clinical trial, Elores was proven to be non-inferior to meropenem for treatment of patients suffering from complicated urinary tract infections, including acute pyelonephritis, Cipla said.
"I'm positive that Cipla will expand the reach of Elores to many more patients in India while ensuring a similar commitment to anti-microbial stewardship," Venus Medicine Research Centre CEO Saransh Chaudhary said.
Cipla is the third largest pharmaceutical company in India, as per the filing.